89bio Publishes Positive Results from Phase 2 ENTRIGUE
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety...
Source: globenewswire.com
Page 2 - Bryan Martins News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Bryan Martins. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Bryan Martins Today - Breaking & Trending Today
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety and tolerability profile – – SHTG Phase 3 ENTRUST trial initiated in May 2...
Source: marketscreener.com
Data from 89bio's ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints – – New data showed pegozafermin resulted in sig...
Source: marketscreener.com
Data from 89bio's ENLIVEN Phase 2b Trial of Pegozafermin in
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on...
Source: globenewswire.com
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine - 89bio (NASDAQ:ETNB)
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin's favorable safety and tolerability profile – – SHTG Phase 3 ENTRUST trial
Source: benzinga.com